Sarepta Therapeutics released the 168 week data for their exon skipping drug, eteplirsen, this morning. During a three year period, 7-13 year old boys with Duchenne (the age range of […]
Pfizer Inc. (NYSE:PFE) announced today enrollment of the first patient in a multicenter Phase II clinical trial of the investigational compound PF-06252616 in boys with Duchenne muscular dystrophy (DMD), a […]
Last weekend, I had the honor, along with Dr. Mike Kelly, CureDuchenne’s Chief Scientific Officer, and other TACT members, to review Duchenne research projects. CureDuchenne was able to look […]
Those who live with Duchenne muscular dystrophy have physical activity limitations that need to be addressed at school. It is important for those impacted with Duchenne to be included without further […]
Sarepta provided an 144 week update on eteplirsen at the World Muscle Society meeting. Here are some brief notes. Neutral charge as it passes through kidney; cleared through kidney […]
WMS Berlin continues to deliver evolving data and novel insights into the treatment, study and diagnosis of Duchenne Muscular Dystrophy. The location in one of the historical districts for Berlin […]
CureDuchenne is delighted to share the news that Prosensa announced today that it has begun the submission process for a New Drug Application filing to the FDA for its lead […]
The world’s leading experts in the neuromuscular field have gathered in Berlin this week for the World Muscle Society meeting. The focus of the 19th Annual Congress of the World […]
CureDuchenne is proud to have supported all types of Duchenne research over the past 10 years. That is why CureDuchenne has been a leader in funding exon skipping, stop codon, […]
